Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836574 · ClinicalTrials.gov registry record · Phase 2
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
A Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Prokidney.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 16
- Study locations
NCT02836574 is a Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease that has completed, run by Prokidney. The registered enrollment target is 83 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 15 states.
The verdict
NCT02836574, a Phase 2 study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 16
- Study locations
Study Summary
To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).
Conditions Studied
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
- PROCEDURE Renal Biopsy
Study Locations (16)
Michigan
- University of Michigan - Ann Arbor
- Paragon Health - Kalamazoo
Arizona
- University of Arizona - Tucson
Colorado
- Kidney Associates of Colorado - Denver
Connecticut
- Yale Univeristy - New Haven
Florida
- University of Florida - Gainesville
Idaho
- Boise Kidney and Hypertension Institute - Meridian
Illinois
- University of Chicago Medical Center - Chicago
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-09 |
| Est. Completion | 2023-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02836574
The ClinicalTrials.gov registry entry for NCT02836574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT02836574 reports 16 study locations spanning 15 distinct geographic areas - top geographies include Michigan, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT02836574 about?
NCT02836574 is a clinical study titled "A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease". To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).
What is the current status of trial NCT02836574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2016-09. Estimated completion is 2023-12.
What conditions does trial NCT02836574 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease.
What interventions are being tested in trial NCT02836574?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL), Renal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02836574?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02836574 being conducted?
This trial has 16 study locations across Arizona, Colorado, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.